18 and older, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Parkinson's Key GenePrimary· 3 days
The blood of patients were taken for genetic testing and relative expression levels of the genes(These genes expression relative to a house keeping gene:GAPDH) for PPP2CA, PPP3CB, SYNJ1, NSF were extracted.The method we used is RT-PCR.
PPP2CA
Group
Value
95% CI
Parkinson's Disease Group
1.502
0.718 – 3.110
Healthy Controls
3.653
1.990 – 5.856
Parkinson-plus Syndrome Group
0.916
0.654 – 1.452
PPP3CB
Group
Value
95% CI
Parkinson's Disease Group
1.669
0.792 – 2.947
Healthy Controls
2.237
0.903 – 4.416
Parkinson-plus Syndrome Group
2.320
1.110 – 3.269
SYNJ1
Group
Value
95% CI
Parkinson's Disease Group
0.924
0.537 – 1.585
Healthy Controls
4.662
2.278 – 7.452
Parkinson-plus Syndrome Group
5.206
2.541 – 6.150
NSF
Group
Value
95% CI
Parkinson's Disease Group
1.002
0.513 – 2.150
Healthy Controls
3.058
1.665 – 4.909
Parkinson-plus Syndrome Group
1.408
0.864 – 2.689
Unified Parkinson's Disease Rating Scale 3.0（UPDRS 3.0）Primary· 2 days
The total score ranges from 0 to 199( minimum score is 0 and maximum scores is 199), in which a lower score denotes a better perception of the patient's.
Scoring the mental, behavioral and emotional, daily living activities, exercise tests, and drug treatment complications associated with UPDRS3.0 in patients with Parkinson's disease;each item 0-4 points, total score 199 points, 0-50 points: limb and body mild dysfunction, posture response normal;51-100 points: mild postural reaction disorder, self-care in daily life, loss of labor force;101-199: obvious postural reaction disorder, loss of da
Group
Value
95% CI
Parkinson's Disease Group
61.352
± 29.611
Sponsor's own description
The research team used meta-analytical statistical methods to integrate the results of different research groups on Parkinson's disease, using meta-analysis to find key genes related to the pathogenesis and development of Parkinson's disease, and to make small clinical results. The verification of the sample, the internal mechanism of the pathogenesis of Parkinson's disease and provide guidance and reference for subsequent experimental research.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite
· recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease
· Phase 4
· recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's
· NA
· recruiting
NCT06562569 — Non-invasive VNS for PD Gait
· NA
· recruiting
Other Zhujiang Hospital trials
Trials by the same sponsor.
NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym
· EARLY_PHASE1
· not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t
· Phase 2
· recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit
· not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a
· not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients
· Phase 1, PHASE2
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 28 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03848455.